Update on acute myeloid leukemia stem cells: New discoveries and therapeutic opportunities

doi:10.4252/wjsc.v8.i10.316

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 10

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (11822)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-2) series.

Item

Count

PDF

714

WORD

313

HTML

5611

Figures (1-1)

392

Tables (1-2)

290

Sum=7320

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

540

Download

1267

Sum=1807

Publishing Process of This Article

Item

Count

Browse

1212

Download

1483

Sum=2695

Oct 26, 2016 (publication date) through Feb 15, 2025

Times Cited of This Article

Times Cited (15)

Journal Information of This Article

Publication Name

World Journal of Stem Cells

ISSN

1948-0210

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Stem Cells. Oct 26, 2016; 8(10): 316-331
Published online Oct 26, 2016. doi: 10.4252/wjsc.v8.i10.316

Table 1 Markers of leukemia stem cells

Cell surfacemarkers	Patient samples used	Mouse model used	Ref.
CD34⁺CD38^-	FAB M1, M4, M5	NOD/SCID	[15,16]
CD34⁺CD38⁺	CN-AML, MLL-ENL	NOD/SCID + IVIG or anti-CD122	[18,64,67,68]
CD34^-CD38⁺	AML with NPM1 mutation	NOD/SCID β-2 microglobulin NOD/SCID IL2 receptor γ^−/− + IVIG	[66]
CD34⁺CD123⁺	FAB M1, M2, M4	NOD/SCID	[69]
CD34⁺CD38^-CD96⁺	CK-AML, CBFB-MYH11, PML-RARA, AML1-ETO, FAB M4	Rag2^-/- IL2RG^-/-	[70]
CD34⁺CLL1⁺	AMLs with FLT3-ITD	NOD/SCID	[71]
TIM3⁺	FAB M1, M2, M4	NOD/Rag1^-/- IL2RG^-/-	[72]
CD34⁺CD38^- CD33⁺CD13⁺	CN-AML, CBF-AML, MLL-ENL	NOD/SCID	[73]

FAB: French-American-British classification system; CN: Cytogenetically normal; CK: Cytogenetically complex; MLL-ENL: Mixed-lineage leukemia-eleven nineteen leukemia; NPM1: Nucleophosmin 1; CBFB-MYH11: Core binding factor beta unit-Myosin heavy chain 11; PML-RARA: Promyelocytic leukemia-retinoic acid receptor alpha; AML1-ETO: Acute myeloid leukemia 1 protein- eight twenty one; FLT3-ITD: Fms-like tyrosine kinase 3 Internal tandem duplication; NOD/SCID: Non-obese diabetic/severe combined immunodeficiency; Rag: Recombination activating gene; IL2RG: Interleukin 2 receptor subunit gamma.

Citation: Stahl M, Kim TK, Zeidan AM. Update on acute myeloid leukemia stem cells: New discoveries and therapeutic opportunities. World J Stem Cells 2016; 8(10): 316-331
URL: https://www.wjgnet.com/1948-0210/full/v8/i10/316.htm
DOI: https://dx.doi.org/10.4252/wjsc.v8.i10.316